Tom Grimes
Research Scientist
Tom graduated from Durham University in 2017 with an MChem degree in Chemistry. He spent the final year of his degree within the Epigenetics department at GSK in Stevenage working on the "Synthesis and bioactivity of BET bromodomain inhibitors." Following his degree, Tom worked for two years as a Research Scientist for AMRI based at the Eli Lilly Erl Wood site. He provided synthetic organic chemistry support for a wide variety of Eli Lilly and Elanco projects.
Tom joined the Brennan Group in July 2019 to work as part of the Alzheimer's Research UK Oxford Drug Discovery Institute.
Recent publications
-
Covalent Inhibitors of S100A4 Block the Formation of a Pro-Metastasis Non-Muscle Myosin 2A Complex.
Journal article
Giroud C. et al, (2024), Journal of medicinal chemistry
-
Synthesis of meta-substituted arene bioisosteres from [3.1.1]propellane
Journal article
Frank N. et al, (2022), Nature, 611, 721 - 726
-
Synthesis of meta-substituted arene bioisosteres from [3.1.1]propellane
Preprint
Frank N. et al, (2022)
-
Optimization of a Series of 2,3-Dihydrobenzofurans as Highly Potent, Second Bromodomain (BD2)-Selective, Bromo and Extra-Terminal Domain (BET) Inhibitors
Journal article
Lucas SCC. et al, (2021), Journal of Medicinal Chemistry, 64, 10711 - 10741